Cote Elissa S. reported VTGN

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0002069951-26-000004

Machine-readable

Structured copy

Timestamps

Event (reported)

Apr 7, 2026

Published

Apr 9, 2026

Ingested by INSIDER

Nov 5, 04:05 UTC

Last re-read

Nov 5, 04:05 UTC

Extracted facts

Filer

Cote Elissa S.

Role

Chief Corp Development Officer

Transaction

Grant or awardAs filed: “A”

Asset

Vistagen Therapeutics, Inc. — Incentive Stock Option (right to buy)

Ticker

VTGN

Shares

75.0K

Price per share

$0

Execution date (reported)

Apr 7, 2026

Owned after transaction

75.0K shares

Days from execution to publication

2

What this establishes

Cote Elissa S. filed this Form 4 reporting a grant or award of VTGN on Apr 7, 2026. It became public on Apr 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Chief Corp Development Officer

Cote Elissa S.cik:0002069951

Issuer

Vistagen Therapeutics, Inc.cik:0001411685

Revision history · 0

No field has changed since this record was first ingested.